The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Alterations of immune response of non-small cell lung cancer with Azacytidine
Open accessAbstract
// John Wrangle 1* , Wei Wang 2* , Alexander Koch 3* , Hariharan Easwaran 4 , Helai P. Mohammad 5 , Xiaoyu Pan 4 ,Frank Vendetti 4 , Wim VanCriekinge 3 , Timothy DeMeyer 3 , Zhengzong Du 4 , Princy Parsana 6 , Kristen Rodgers 4 , Ray-Whay Yen 4 , Cynthia A. Zahnow 4 , Janis M. Taube 7 , Julie R. Brahmer 4 , Scott S. Tykodi 10 , Keith Easton 10 , Richard D. Carvajal 11 , Peter A. Jones 8 , Peter W. Laird 8 , Daniel J. Weisenberger 8 , Salina Tsai 9 , Rosalyn A. Juergens 4 , Suzanne L. Topalian 12 , Charles M. Rudin 4** , Malcolm V. Brock 4** , Drew Pardoll 4** , and Stephen B. Baylin 4** 1 The Johns Hopkins University, School of Medicine, Oncology Center-Hematology/Medical Oncology, Baltimore, Maryland 2 The Johns Hopkins University, School of Medicine, Human Genetics Graduate Program, Baltimore, Maryland 3 Departments of Molecular Biotechnology, Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium 4 The Johns Hopkins University, School of Medicine, Oncology, Baltimore, Maryland 5 GlaxoSmithKline Pharmaceuticals, Cancer Epigenetics and Oncology, Collegeville, Pennsylvania 6 The Johns Hopkins University, Advanced Academic Bioinformatics, Baltimore, Maryland 7 The Johns Hopkins University, School of Medicine, Dermatology and Oral Pathology, Baltimore, Maryland 8 USC Epigenome Center, Keck School of Medicine, University of Southern California, Los Angeles, California 9 The Johns Hopkins University, School of Medicine, Russell H. Morgan Department of Radiology and Radiological Science, Baltimore, Maryland 10 University of Washington and Fred Hutchison Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington 11 Memorial Sloan-Kettering Cancer Center, New York, New York 12 The Johns Hopkins University, School of Medicine, Surgery, Baltimore, Maryland * These authors contributed equally Correspondence: Stephen B. Baylin, email: // Keywords : Non-Small Cell Lung Cancer(NSCLC), Azacytidine, HDAC inhibitor Received : October 18, 2013 Accepted : October 25, 2013 Published : October 25, 2013 Abstract Innovative therapies are needed for advanced Non-Small Cell Lung Cancer (NSCLC). We have undertaken a genomics based, hypothesis driving, approach to query an emerging potential that epigenetic therapy may sensitize to immune checkpoint therapy targeting PD-L1/PD-1 interaction. NSCLC cell lines were treated with the DNA hypomethylating agent azacytidine (AZA - Vidaza) and genes and pathways altered were mapped by genome-wide expression and DNA methylation analyses. AZA-induced pathways were analyzed in The Cancer Genome Atlas (TCGA) project by mapping the derived gene signatures in hundreds of lung adeno (LUAD) and squamous cell carcinoma (LUSC) samples. AZA up-regulates genes and pathways related to both innate and adaptive immunity and genes related to immune evasion in a several NSCLC lines. DNA hypermethylation and low expression of IRF7, an interferon transcription factor, tracks with this signature particularly in LUSC. In concert with these events, AZA up-regulates PD-L1 transcripts and protein, a key ligand-mediator of immune tolerance. Analysis of TCGA samples demonstrates that a significant proportion of primary NSCLC have low expression of AZA-induced immune genes, including PD-L1. We hypothesize that epigenetic therapy combined with blockade of immune checkpoints – in particular the PD-1/PD-L1 pathway - may augment response of NSCLC by shifting the balance between immune activation and immune inhibition, particularly in a subset of NSCLC with low expression of these pathways. Our studies define a biomarker strategy for response in a recently initiated trial to examine the potential of epigenetic therapy to sensitize patients with NSCLC to PD-1 immune checkpoint blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: MAVS protects cells from apoptosis by negatively regulating VDAC1
Xu, Y., Zhong, H., & Shi, W. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0658-4 · Cited by 8
RetractedSubramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationBioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Self-citationCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759 · cited 1×
“The re-expressed genes in the above mentioned pathways are downstream targets of interferon response pathways in a fashion closely linked to pro-inflammatory and viral defense responses [28-31].”
BackgroundInflammasomes in health and disease
Strowig, T., Henao-Mejia, J., Elinav, E., & Flavell, R. (2012) · Nature · doi:10.1038/nature10759 · Cited by 2,230
Mammalian autophagy: core molecular machinery and signaling regulation
Yang, Z., & Klionsky, D. J. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.11.014 · Cited by 1,956
Normalization of cDNA microarray data
Smyth, G. K., & Speed, T. (2003) · Methods · doi:10.1016/s1046-2023(03)00155-5 · Cited by 1,871
Silverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D., Powell, B. L., DeCastro, C. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.117 · Cited by 1,825
GSEA-P: a desktop application for Gene Set Enrichment Analysis
Subramanian, A., Kuehn, H., Gould, J., Tamayo, P., & Mesirov, J. P. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm369 · Cited by 1,390
Reactome: a knowledgebase of biological pathways
Joshi-Tope, G. (2004) · Nucleic Acids Research · doi:10.1093/nar/gki072 · Cited by 1,290
Natural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells
Rhee, I., Bachman, K. E., Park, B. H., Jair, K.-W., Yen, R.-W. C., Schuebel, K. E., Cui, H., Feinberg, A. P., Lengauer, C., Kinzler, K. W., et al. (2002) · Nature · doi:10.1038/416552a · Cited by 1,039
Self-citationModes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
Stresemann, C., & Lyko, F. (2008) · International Journal of Cancer · doi:10.1002/ijc.23607 · Cited by 949
The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends
Youlden, D. R., Cramb, S. M., & Baade, P. D. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31818020eb · Cited by 812
An atlas of combinatorial transcriptional regulation in mouse and man
Ravasi, T., Suzuki, H., Cannistraci, C. V., Katayama, S., Bajic, V. B., Tan, K., Akalin, A., Schmeier, S., Kanamori-Katayama, M., Bertin, N., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.044 · Cited by 715
Juergens, R. A., Wrangle, J., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0214 · Cited by 686
Self-citationTsai, H.-C., Li, H., Van Neste, L., Cai, Y., Robert, C., Rassool, F. V., Shin, J. J., Harbom, K. M., Beaty, R., Pappou, E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.029 · Cited by 650
Self-citationCovalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine.
Santi, D. V., Norment, A., & Garrett, C. E. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.22.6993 · Cited by 518
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
Bidwell, B. N., Slaney, C. Y., Withana, N. P., Forster, S., Cao, Y., Loi, S., Andrews, D., Mikeska, T., Mangan, N. E., Samarajiwa, S. A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2830 · Cited by 487
Challa-Malladi, M., Lieu, Y. K., Califano, O., Holmes, A. B., Bhagat, G., Murty, V. V., Dominguez-Sola, D., Pasqualucci, L., & Dalla-Favera, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.006 · Cited by 439
Zambelli, F., Pesole, G., & Pavesi, G. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp464 · Cited by 402
DNA Methylation Screening Identifies Driver Epigenetic Events of Cancer Cell Survival
De Carvalho, D. D., Sharma, S., You, J. S., Su, S.-F., Taberlay, P. C., Kelly, T. K., Yang, X., Liang, G., & Jones, P. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.045 · Cited by 285
Self-citationINTERFEROME: the database of interferon regulated genes
Samarajiwa, S. A., Forster, S., Auchettl, K., & Hertzog, P. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn732 · Cited by 265
Karpf, A. R., Peterson, P. W., Rawlins, J. T., Dalley, B. K., Yang, Q., Albertsen, H., & Jones, D. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.14007 · Cited by 196
REACTOME: A KNOWLEDGEBASE OF BIOLOGICAL PATHWAYS
Stein, L., D'Eustachio, P., Gopinathrao, G., Gillespie, M., Matthews, L., Wu, G., Vastrik, I., Schmidt, E., de Bono, B., Jassal, B., et al. (2006) · Computational Systems Bioinformatics · doi:10.1142/9781860947575_0009 · Cited by 182
Regulation of the Promoter Activity of Interferon Regulatory Factor-7 Gene
Lu, R., Au, W.-C., Yeow, W.-S., Hageman, N., & Pitha, P. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005288200 · Cited by 163
Epigenetic silencing of multiple interferon pathway genes after cellular immortalization
Kulaeva, O. I., Drăghici, S., Tang, L., Kraniak, J. M., Land, S. J., & Tainsky, M. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206594 · Cited by 144
Emerging Roles of FAM14 Family Members (G1P3/ISG 6–16 and ISG12/IFI27) in Innate Immunity and Cancer
Cheriyath, V., Leaman, D. W., & Borden, E. C. (2010) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0105 · Cited by 140
Fonsatti, E., Nicolay, H. J. M., Sigalotti, L., Calabrò, L., Pezzani, L., Colizzi, F., Altomonte, M., Guidoboni, M., Marincola, F. M., & Maio, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3091 · Cited by 135
Epigenetic regulation of immune escape genes in cancer
Tomasi, T. B., Magner, W. J., & Khan, A. N. H. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0164-4 · Cited by 132
KEGG OC: a large-scale automatic construction of taxonomy-based ortholog clusters
Nakaya, A., Katayama, T., Itoh, M., Hiranuka, K., Kawashima, S., Moriya, Y., Okuda, S., Tanaka, M., Tokimatsu, T., Yamanishi, Y., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1239 · Cited by 129
MHC class I assembly: out and about
Raghavan, M., Cid, N. D., Rizvi, S. M., & Peters, L. R. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.06.004 · Cited by 110
Gabbara, S., & Bhagwat, A. S. (1995) · Biochemical Journal · doi:10.1042/bj3070087 · Cited by 94
Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma
Jee, C. D., Kim, M. A., Jung, E. J., Kim, J., & Kim, W. H. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.12.027 · Cited by 94
Carretero, R., Wang, E., Rodríguez, A. I. E., Reinboth, J., Ascierto, M. L., Engle, A. M., Liu, H., Camacho, F. M., Marincola, F. M., Garrido, F., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26471 · Cited by 88
Brahmer, J. R., Horn, L., Antonia, S. J., Spigel, D. R., Gandhi, L., Sequist, L. V. D., Sankar, V., Ahlers, C. M., Wigginton, J. M., Kollia, G. D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8030 · Cited by 74
Self-citationLi, Q., & Tainsky, M. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028683 · Cited by 73
Epigenetic Treatment of Hematopoietic Malignancies: In Vivo Targets of Demethylating Agents
Claus, R., Almstedt, M., & Lübbert, M. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.07.024 · Cited by 65
Antigen processing and presentation: TAPping into ABC transporters
Procko, E., & Gaudet, R. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.003 · Cited by 54
Šímová, J., Polláková, V., Indrová, M., Mikyšková, R., Bieblová, J., Štěpánek, I., Bubenik, J., & Reiniš, M. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.428 · Cited by 47
Lopez, F., Textoris, J., Bergon, A., Didier, G., Rémy, É., Granjeaud, S., Imbert, J., Nguyen, C., & Puthier, D. (2008) · PLoS ONE · doi:10.1371/journal.pone.0004001 · Cited by 38
Hsu, T., Chu, C., Jiang, S., Hung, M.-W., Ni, W.-C., Lin, H.-E., & Chang, T. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.03.020 · Cited by 30
Personalized medicine and treatment approaches in non-small-cell lung carcinoma
Borghaei, H. (2012) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s24258 · Cited by 24
Viral Defense: It Takes Two MAVS to Tango
Sharma, S., & Fitzgerald, K. A. (2010) · Cell · doi:10.1016/j.cell.2010.04.043 · Cited by 12
Vaquerizas, J. M., Teichmann, S. A., & Luscombe, N. M. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-292-2_1 · Cited by 8
Large-Scale Nuclear Architecture and Transcriptional Control
Vaquerizas, J. M., Akhtar, A., & Luscombe, N. M. (2011) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-90-481-9069-0_13 · Cited by 5
Cited by
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
Self-citationRoulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang, G., Jones, P. A., Pugh, T. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.056 · Cited by 1,527
Self-citationRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Metadata
- Authors
- Wrangle, J., Wang, W., Koch, A., Easwaran, H., Mohammad, H. P., Pan, X., Vendetti, F., VanCriekinge, W., DeMeyer, T., Du, Z., Parsana, P., Rodgers, K., Yen, R.-W., Zahnow, C. A., Taube, J. M., Brahmer, J. R., Tykodi, S. S., Easton, K., Carvajal, R. D., Jones, P. A., Laird, P. W., Weisenberger, D. J., Tsai, S., Juergens, R. A., Topalian, S. L., Rudin, C. M., Brock, M. V., Pardoll, D., & Baylin, S. B.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2013-10-25
- Volume
- 4
- Issue
- 11
- Pages
- 2067-2079
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1827923022
- Cited by
- 386
- References
- 55
- FWCI
- 14.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.